In contrast, PD-1 had basically no effect on PFS, but if the model was adjusted for the presence of hepatic metastases, the presence of carcinosis peritonei, or whether the tumor was operable/inoperable, higher PD-1 levels indicated inferior survival outcomes of mCRC patients (Table 3). This evidence concerns the gene PDCD1 and neoplasm.